Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients

Journal of B.U.ON.

Volumn 13, Issue 1, 2008, Pages 69-74

  Zissimopoulos, A ^a   Bantis, A ^a   Stellos, K ^b   Petrakis, G ^c   Matthaios, Dimitrios ^a  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bone metastases; Bone scan; Procollagen (I) carboxyterminal propeptide; Prostate adenocarcinoma; Prostate specific antigen

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GREECE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 41549091358     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Eble J, Sauter G, Epstein J, Sesterhenn I. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Cancer Incidence, Mortality and Prevalence Worldwide, Globocan 2002, American Cancer Society. CA Cancer J Clin 2005; 55: 74-108.
3. Elder JS, Catalona WJ. Management of newly metastatic carcinoma of the prostate. Urol Clin North Am 1984; 11: 283-295.
4. Stoll BA. Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbho S (Eds): Bone metastases monitoring and treatment. New York: Raven Press, 1983, pp 1-4.
5. Jacobs S. Spread of prostatic cancer to bone. Urology 1983; 21: 337-344.
6. Smith PH, Bono A, Calais da Silva F et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer 1990; 66 (5 Suppl): 1009-1016.
7. Akimoto S, Koichiro A, Shimazaki J. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. J Clin Oncol 1996; 26: 157-163.
8. Fleming I, Cooper J, Henson D et al (Eds): AJCC Cancer Staging Handbook (5th edn). Lippincott, Williams & Wilkins, Philadelphia, 1998, p 203.
9. Joerring S, Jensen LT, Andersen GR, Johansen JS. Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 1992; 111: 265-267.
10. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 1994; 55: 90-93.
11. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 1984; 58: 110-120.
12. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
13. Grammaticos P. Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma. Hell J Nucl Med 2004; 7: 146-148.
14. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991; 12 (Suppl 1): S1-S6.
15. Thompson IM, Phyllis MD. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 3: 215-224.
16. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992; 74: 471-475.
17. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25: 236-242.
18. Masanori N, Shinshi N. Pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001; 166: 1106-1110.
19. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridoniline cross-linked carboxy-terminal telopeptide of type 1 collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.
20. Francini G, Gonnelli S, Petrioli R et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev 1993; 2: 125-129.
21. Nakashima J, Sumitomo M, Miyajima A et al. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol 1997; 157: 1736-1739.
22. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71: 1061-1064.
23. McNeal JE, Bostwick DG, Kindrachuck RA et al. Patterns of progression in prostate cancer. Lancet 1986; 1: 60-63.
24. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-1351.
25. Koizumi M, Yamada Y, Takiguchi T et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995; 121: 542-548.
26. Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma. Eur Urol 1997; 31: 220-223.
27. Santi I, Monti M, Vigano A et al. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases. Int J Biol Markers 1995; 10: 107-112.
28. Fukumitsu N, Uchiyama M, Mori Y, Kishimoto K, Nakada J. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients. Ann Nucl Med 2003; 17: 297-303.
29. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003; 61: 993-998.
30. Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA. Serum amino-terminal propeptide of type 1 procollagen (PINP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 2006; 76: 67-71.